Literature DB >> 33994740

Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma.

Animesh Saurabh1, Vandana Raphael1, Biswajit Dey1, Caleb Harris2, Vikas Jagtap3, Umesh Das4.   

Abstract

The process of tumorigenesis in gastric carcinoma involves multiple genetic alterations including overexpression of PD-L1, amplification of Her2neu, and mutation of p53. In the present study, the expressions of PD-L1 and Her2neu were analyzed in relation to clinicopathological parameters including p53 in gastric and gastroesophageal junction adenocarcinoma. We examined 100 biopsy and resection samples of gastric and gastroesophageal junction carcinomas for PD-L1, Her2neu, and p53 protein expressions using immunohistochemistry. Scorings were done based on intensity and percentage of tumor cells expressing the markers. Follow-up and survival analyses were done wherever data was available. PD-L1 and Her2neu were seen in 37% and 38% respectively. The analysis showed PD-L1 expression was significantly associated with depth of invasion (p = 0.0007), nodal metastasis (p = 0.0003), and AJCC staging (p = 0.0085). Her2neu negative including equivocal expression was significantly associated with histological grading (p = 0.0043), Lauren classification (p = 0.0042), depth of invasion (p = 0.04), and nodal metastasis (p = 0.017). Combined analysis of PD-L1 and Her2neu showed significant association with histological grading (p = 0.017), Lauren classification (p = 0.005), depth of invasion (p = 0.0035), and nodal metastasis (p = 0.00073). Univariate Cox regression analysis showed that depth of invasion, nodal metastasis, distant metastasis, AJCC staging, and p53 were negative prognostic factors for patients' overall survival. In multivariate analysis, distant metastasis and Her2neu negativity including equivocal cases were independent prognostic factors. PD-L1 positivity was seen in cases with advanced pathological features, which suggest its role in the tumorigenesis of gastric and gastroesophageal junction adenocarcinoma. Her2neu positivity showed no correlation with advanced pathological features as well as no prognostic significance, which could be attributed to tumor heterogeneity, endoscopic nature of the biopsies, and non-confirmation of equivocal cases by fluorescent in situ hybridization. © Indian Association of Surgical Oncology 2020.

Entities:  

Keywords:  Gastric adenocarcinoma; Her2neu; Immunohistochemistry; PD-L1

Year:  2020        PMID: 33994740      PMCID: PMC8119584          DOI: 10.1007/s13193-020-01245-w

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  21 in total

1.  A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.

Authors:  Junhun Cho; Jiyun Jeong; Jiyoun Sung; Chang Ohk Sung; Kyoung-Mee Kim; Cheol Keun Park; Min Gew Choi; Tae Sung Sohn; Jae Moon Bae; Sung Kim
Journal:  Ann Surg Oncol       Date:  2012-12-30       Impact factor: 5.344

2.  Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.

Authors:  Tatsuro Tamura; Masaichi Ohira; Hiroaki Tanaka; Kazuya Muguruma; Takahiro Toyokawa; Naoshi Kubo; Katsunobu Sakurai; Ryosuke Amano; Kenjiro Kimura; Masatsune Shibutani; Kiyoshi Maeda; Kosei Hirakawa
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

3.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

4.  Importance of EGF receptor, HER2/Neu and Erk1/2 kinase signalling for host cell elongation and scattering induced by the Helicobacter pylori CagA protein: antagonistic effects of the vacuolating cytotoxin VacA.

Authors:  Nicole Tegtmeyer; Dana Zabler; Diana Schmidt; Roland Hartig; Sabine Brandt; Steffen Backert
Journal:  Cell Microbiol       Date:  2008-11-25       Impact factor: 3.715

5.  Anti program death-1/anti program death-ligand 1 in digestive cancers.

Authors:  Eléonore de Guillebon; Pauline Roussille; Eric Frouin; David Tougeron
Journal:  World J Gastrointest Oncol       Date:  2015-08-15

Review 6.  HER2 testing in gastric cancer: An update.

Authors:  Lucas Faria Abrahao-Machado; Cristovam Scapulatempo-Neto
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

7.  HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature.

Authors:  Jan Trøst Jørgensen; Maria Hersom
Journal:  J Cancer       Date:  2012-03-12       Impact factor: 4.207

8.  Immunohistochemical Analysis of p53, Ki-67, CD44, HER-2/neu Expression Patterns in Gastric Cancer, and Their Association with One Year Survival in North-West of Iran.

Authors:  Zohreh Sanaat; Monireh Halimi; Morteza Ghojezadeh; Amir Hossein Pirovi; Jalil Vaez Gharamaleki; Ali Esfahani Jamal Eivazi Ziae; Iraj Aswadi Kermani
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013

9.  HER2 expression status in diverse cancers: review of results from 37,992 patients.

Authors:  Min Yan; Maria Schwaederle; David Arguello; Sherri Z Millis; Zoran Gatalica; Razelle Kurzrock
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

10.  Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections.

Authors:  Renato Santos Laboissiere; Marcelo Araújo Buzelin; Débora Balabram; Marina De Brot; Cristiana Buzelin Nunes; Rafael Malagoli Rocha; Mônica Maria Demas Álvares Cabral; Helenice Gobbi
Journal:  BMC Gastroenterol       Date:  2015-11-04       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.